emberroot Pharmaceuticals | Transforming Lives Through Science

About Us

Rooted in Science. Driven by Purpose.

Founded with the mission to transform patients' lives, emberroot Pharmaceuticals is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines in oncology, immunology, neuroscience, and rare diseases.

Our integrated research platform combines small molecule chemistry, biologics engineering, gene therapy, and advanced drug delivery to address unmet medical needs. With research facilities spanning three continents, we bring together world-class scientists, clinicians, and industry experts united by a shared commitment to scientific excellence.

We believe that breakthrough science, pursued with integrity and urgency, has the power to change the trajectory of human health. Every day, our teams work to translate complex biology into medicines that make a meaningful difference for patients and their families.

Our Therapeutic Portfolio

Delivering innovative treatments across multiple high-impact disease areas

🧬

Oncology

Targeted therapies and immuno-oncology agents designed to address solid tumors and hematologic malignancies. Our portfolio includes checkpoint inhibitors, antibody-drug conjugates, and bispecific antibodies currently in use across 22 countries.

🧠

Neuroscience

Novel approaches to neurodegenerative and neuropsychiatric disorders. Our pipeline addresses Alzheimer's disease, Parkinson's disease, and treatment-resistant depression through innovative mechanisms of action.

🧪

Immunology

Precision immunology therapies targeting autoimmune and inflammatory conditions. Our approved treatments help patients with rheumatoid arthritis, psoriasis, and inflammatory bowel disease achieve lasting remission.

🩺

Rare Diseases

Gene therapies and enzyme replacement treatments for patients with rare genetic disorders. We are committed to serving small patient populations with transformative, often curative approaches.

❤️

Cardiovascular

Next-generation lipid-lowering agents, anticoagulants, and heart failure therapeutics. Our cardiovascular portfolio focuses on reducing major adverse cardiac events and improving long-term outcomes.

💊

Specialty Generics & Biosimilars

High-quality biosimilars and complex generics that expand patient access to essential medicines. Our manufacturing capabilities ensure reliable global supply at competitive pricing.

Research Pipeline

A robust portfolio of investigational medicines advancing through clinical development

Candidate	Indication	Modality	Phase
EMR-4471	Non-Small Cell Lung Cancer	Bispecific Antibody	Phase 3
EMR-2289	Moderate-to-Severe Psoriasis	IL-17 Inhibitor	Phase 3
EMR-5510	Alzheimer's Disease (Early Stage)	Anti-Amyloid mAb	Phase 2
EMR-1037	Hereditary Transthyretin Amyloidosis	Gene Therapy (AAV)	Phase 2
EMR-8823	Treatment-Resistant Depression	NMDA Receptor Modulator	Phase 1
EMR-6190	Advanced Hepatocellular Carcinoma	Antibody-Drug Conjugate	Phase 1

Industry Trends & Our Response

How emberroot Pharmaceuticals is positioned to lead in a rapidly evolving landscape

AI & Machine Learning

AI-Driven Drug Discovery

The pharmaceutical industry is rapidly adopting artificial intelligence to accelerate target identification and lead optimization. emberroot has invested heavily in computational biology platforms that reduce discovery timelines by up to 40%, enabling faster progression from bench to bedside.

Precision Medicine

Biomarker-Guided Therapeutics

Precision medicine is transforming how therapies are developed and prescribed. Our clinical programs incorporate companion diagnostics and genomic stratification from Phase 1, ensuring our medicines reach the patients most likely to benefit.

Cell & Gene Therapy

Next-Generation Genetic Medicines

Gene therapy and cell-based treatments offer curative potential for previously untreatable conditions. emberroot's gene therapy platform leverages novel AAV capsids and lipid nanoparticle delivery systems for durable, one-time treatments.

Patient Access

Global Access & Value-Based Models

Affordable access to innovative medicines remains a critical challenge. We pioneer outcomes-based agreements and tiered pricing structures across markets, ensuring our therapies are accessible regardless of geography or healthcare system.

Sustainability

Green Chemistry & Sustainable Manufacturing

Environmental sustainability in pharmaceutical manufacturing is no longer optional. Our facilities utilize continuous flow chemistry, solvent recovery systems, and renewable energy, reducing our carbon footprint by 55% since 2019.

Digital Health

Decentralized Clinical Trials

The industry shift toward hybrid and decentralized trial models improves diversity and retention. emberroot employs wearable sensors, telemedicine visits, and direct-to-patient drug delivery across our Phase 2 and Phase 3 programs.

Executive Leadership

Experienced leaders driving scientific innovation and operational excellence

DM

Dr. Darian Marchetti

Chief Executive Officer

Over 25 years of leadership in global biopharmaceutical organizations. Previously held executive roles overseeing commercial operations and R&D strategy at large-cap pharmaceutical companies. Holds an M.D. from a top-tier medical school with residency training in internal medicine and a subsequent MBA.

SK

Dr. Solene Kitagawa

Chief Scientific Officer

Distinguished researcher with 18 years in drug discovery and translational science. Led multiple programs from preclinical development through regulatory approval. Published extensively in peer-reviewed journals on molecular pharmacology and immuno-oncology.

RV

Rafael Voss

Chief Financial Officer

Two decades of financial leadership in life sciences and healthcare. Deep expertise in capital markets, M&A transactions, and investor relations. Previously managed treasury and corporate finance functions for publicly traded biotech firms with revenues exceeding $5 billion.

AN

Dr. Amara Ndiaye

Chief Medical Officer

Board-certified oncologist with 20 years of clinical and pharmaceutical development experience. Oversaw global clinical trial programs enrolling 15,000+ patients. Expert in adaptive trial design and regulatory strategy across FDA, EMA, and PMDA.

JH

Julian Herrera

Chief Operating Officer

Experienced operations executive with background in pharmaceutical manufacturing, supply chain optimization, and global commercial launch. Managed facility buildouts and technology transfers across multiple international sites. Six Sigma Black Belt certified.

LT

Dr. Linnea Thorsen

SVP, Head of Regulatory Affairs

15 years navigating complex regulatory pathways across major markets. Led successful submissions resulting in over 20 product approvals globally. Deep expertise in accelerated pathways including breakthrough therapy, fast track, and orphan drug designations.

Community Impact

Our commitment extends beyond the lab — building healthier communities worldwide

Women's Health Programs

We support comprehensive female health initiatives including maternal care access programs in underserved regions, cervical cancer screening campaigns, research grants for women's reproductive health, and mentorship programs for women in STEM fields. Our annual health equity fund has provided preventive screenings to over 200,000 women across rural and urban communities.

Educational Partnerships

Through our academic collaboration programs, we fund undergraduate and graduate STEM scholarships, sponsor laboratory equipment for community colleges, host summer research internships for underrepresented students, and provide continuing education grants for healthcare professionals. Our science education outreach has reached more than 50,000 students since inception.

Environmental Initiatives

Environmental stewardship is embedded in our operations. We maintain zero-waste-to-landfill certification at our primary manufacturing facilities, invest in wetland restoration near operational sites, support clean water access projects in communities where we operate, and have committed to carbon neutrality across all global operations by 2030. Our green chemistry program has eliminated over 3 million liters of hazardous solvent waste annually.

emberroot Health Companion

Track your treatment journey, access medication information, set dosing reminders, and connect with our patient support team — all in one app. Available for iOS and Android.

Science That Ignites Hope

47+

12

8,500+

35